Article Text

Download PDFPDF

713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers
  1. Petr Danek1,
  2. Ekaterina Simonova1,
  3. Nada Podzimkova1,
  4. David Bechard2,
  5. Richard Sachse3,
  6. Joachim Kiemle-Kallee3,
  7. Ulrich Moebius1,
  8. Radek Spisek1,4,
  9. Irena Adkins1,4,
  10. Martin Steegmaier1 and
  11. Lenka Palova Jelinkova1,4
  1. 1Sotio Biotech a.s., Prague, Czech Republic
  2. 2Cytune Pharma, Nantes, France, France
  3. 3SOTIO Biotech AG, Basel, Switzerland
  4. 42nd Faculty of Medicine and University Hospital Motol, Prague 5, Czech Republic


Background Nanrilkefusp alfa (SOT101, RLI-15) is a high affinity superagonist fusion protein of interleukin (IL)-15 and the IL-15 receptor α (IL-15Rα) sushi+ domain representing a promising clinical candidate for the treatment of cancer. Nanrilkefusp alfa induces proliferation and activation of CD8+ T cells, memory CD8+ T cells, NK cells, γ∂ T cells and NKT cells but not T regs.

Methods Blood and tumor samples from patients with advanced/metastatic solid tumors participating in a Phase clinical I study (NCT04234113) were analyzed by flow cytometry, immunohistochemistry and NanoString analyses for immune cells activation and tumor infiltration induced by Nanrilkefusp alfa monotherapy or in combination with pembrolizumab.

Results Nanrilkefusp alfa monotherapy or combined with pembrolizumab markedly increased proliferation of CD8+ T cells, memory CD8+ T cells, NK cells and NKT cells, the absolute NK cell, CD8+ and memory CD8+ T cell counts, as well as IFN-γ levels without concomitantly increasing Tregs in peripheral blood. Whereas strong proliferation of NK cells was detected already at the lowest dose level of 0.25 µg/kg, proliferation of CD8+ T cells, memory CD8+ T cells and NKT cells was dose-dependent, reaching maximal activity at 12 µg/kg. High NK-cell proliferation was maintained over repeated cycles of the treatment, while NKT and CD8+ T cell proliferation peaked in cycle 1 and then declined slightly. In tumor tissues, nanrilkefusp alfa increased the density of NK cells, CD3+, CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs), the CD8+/Treg ratio and the densities of proliferating CD8+ and CD4+ TILs, while Tregs in the tumor remained low. Consistent with the increased number of TILs, nanrilkefusp alfa increased the expression of gene sets related to innate and adaptive immune responses, including NK cell function, Th1 activation, regulation of the immune response, chemokines, and γ∂ T cells. Pharmacodynamic responses were the most pronounced in patients showing a clinical benefit as determined by stable disease or partial response.

Conclusions Nanrilkefusp alfa boosts both the innate and adaptive immune system and induces proinflammatory changes in the microenvironment of multiple tumor types as single-agent and in combination with pembrolizumab. An extended evaluation of nanrilkefusp alfa in combination with pembrolizumab or cetuximab is currently ongoing in phase 2 clinical trials in patients with selected advanced solid tumors (NCT05256381, NCT05619172).

Ethics Approval The study obtained ethics approval and participants gave informed consent before taking part. Comite de Protection des Personnes, CPP Ouest 6 – CPP 1157 ME1; CEIm Hospital Universitari Vall d´Hebron, ID-RTF096; Western Institutional Review Board, 20192896; U.T.MD Anderson Cancer Center Institutional Review Board, 20192896; Multicenter ethics committee University Hospital Brno, 82/20MEK;Ethics committee Masaryk Memorial Cancer Institute, R 22/20.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.